Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-04-04
2009-11-24
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007940
Reexamination Certificate
active
07622262
ABSTRACT:
Disclosed are uses of Gangliosides GM1and/or asialo-GM1substances simulating the carbohydrate portion of said gangliosides with regard to bonding to anti-GM1antibodies and/or anti-ADM1antibodies for producing agents which bind or block anti-GM1antibodies and/or anti-AGM1antibodies which bond to natural killer cells (NKC) or for blocking antigen-presenting cells and producing a T-cell anergy, and for producing an affinity material for the extracorporeal removal of anti-GM1antibodies and/or anti-AGM1antibodies in order to prevent, inhibit, and treat malignant cancers.
REFERENCES:
patent: 4433060 (1984-02-01), Frenzel
patent: 4593091 (1986-06-01), della Valle et al.
patent: 4831021 (1989-05-01), Tubaro et al.
patent: 5443952 (1995-08-01), Pestronk
patent: 5639617 (1997-06-01), Bouhoun
patent: 6756483 (2004-06-01), Bergmann et al.
patent: 2002/0136735 (2002-09-01), Molina et al.
patent: 4227454 (1994-02-01), None
patent: 19847690 (2000-04-01), None
patent: 0656121 (1998-04-01), None
patent: 93/17691 (1993-09-01), None
patent: 99/15201 (1999-04-01), None
patent: 99/40433 (1999-08-01), None
patent: 00/22439 (2000-04-01), None
patent: 01/10877 (2001-05-01), None
patent: 02/17770 (2002-03-01), None
patent: 02/18950 (2002-03-01), None
Marcus D., Ann Neur 1990, 27:S53-S55.
Tockman et al, Cancer Res., 1992, 52:2711s-2718s.
Nishiyama et al, Neuromuscular Disorders, 1993, 3:227-229.
Doxmorov, I.M. et al., “Nanomolar Concentrations of Gangliosides Stimulate Primary Humoral Response”, Biochemistry and Molecular Biology International, vol. 42, No. 1, Jun. 1997, pp. 57-63.
Ryan, John L. et al., “Possible Role for Glycosphingolipids in the Control of Immune Responses”, Eur. J. Immunology, 1979, vol. 9, pp. 171-175.
Ledeen, Robert W. et al., “The Role of GM1and Other Gangliosides in Neuronal Differentiation: Overview and New Findings”, Annals of New York Academy of Sciences, 1998, pp. 161-175.
Hakamori, Sen-itiroh et al., “Functional Role of Glycosphingolipids in Cell Recognition and Signaling”, Journal of Biochemistry, 1995, vol. 118, pp. 1091-1103.
Yates, Allan J. et al., “Ganglioside Modulation of the PDGF Receptor”, Journal of Neuro-Oncology, 1995, vol. 24, pp. 65-73.
Singh, Anup K. et al., “Gangliosides as Receptors for Biological Toxins: Development of Sensitive Fluoroimmunoassays Using Ganglioside-Bearing Liposomes”, Analytical Chemistry, 2000, vol. 72, No. 24, pp. 6019-6024.
Krivan, Howard C. et al., “Many Pulmonary Pathogenic Bacteria Bind Specifically to the Carbohydrate Sequence Ga1NAcβ1-4Gal found in some Glycolipids”, Proc. Natl. Acad. Sci. USA, Aug. 1988, vol. 85, pp. 6157-6161.
Bäckström, Malin et al., “Characterization of an Internal Permissive Site in the Cholera Toxin B-subunit and Insertion of Epitopes from Human Immunodeficiency Virus-1, Hepatitis B Virus and EnterotoxigenicEscherichia coli”, Gene, 1995, vol. 165, pp. 163-171.
Lencer, Wayne I. et al., “Membrane Traffic and the Cellular Uptake of Cholera Toxin” Biochemica et Biophysica Acta 1450, 1999, pp. 177-190.
Ratner, Adam J. et al., “Cystic Fibrosis Pathogens Activate Ca2+-dependent Mitogen-Activated Protein Kinase Signaling Pathways in Airway Epithelial Cells”, Journal of Biological Chemistry, 2001, vol. 276, No. 22, pp. 19267-19275.
Quarles, Richard H. et al., “Autoantibodies Associated with Peripheral Neuropathy”, Muscle & Nerve, Jul. 1999, vol. 22, pp. 800-822.
Isoardo, G. et al., “Anti GM1 and Anti-Sulfatide Antibodies in Polyneuropathies”, Acta Neural Scand, 2001, vol. 103, pp. 180-187.
Press, Rayomond et al., “Temporal Profile of Anti-Ganglioside Antibodies and Their Relation to Clinical Parameters and Treatment in Guillain-Barré Syndrome”, Journal of the Neurological Sciences, 2001, vol. 190, pp. 41-47.
Adams, D. et al., “Predictive Value of Anti GM, Ganglioside Antibodies in Neuromuscular Diseases: A Study of 180 Sera”, Journal of Neuroimmunology, 1991, vol. 32, pp. 223-230.
Yuki, Nobuhiro et al., “Cross-Reactive Antigen Between Nervous Tissue and a Bacterium Elicits Guillain-Barré Syndrome: Molecular Mimicry Between Ganglioside GM1and Lipopolysaccharide from Penner's Serotype 19 ofCampylobacter jejuni”, Biomedical Research, 1992, vol. 13, No. 6, pp. 451-453.
Schwerer, B. et al., “Antibody Cross-Reactivities Between Gangliosides and Lipopolysaccharides ofCampylobacter jejuniSerotypes Associated with Guillain-Barré Syndrome”, Journal of Endotoxin Research, 1995, vol. 2, pp. 395-403.
Bersudsky, Marina et al., “Lipopolysaccharides of aCampylobacter coliIsolate from a Patient with Guillain-Barré Syndrome Display Ganglioside Mimicry”, Neuromuscular Disorders, 2000, vol. 10, pp. 182-186.
Prendergast, Martina et al., “Lipopolysaccharides in the Development of the Guillain-Barré Syndrome and Miller Fischer Syndrome Forms of Acute Inflammatory Peripheral Neuropathies”, Journal of Endotoxin Research, 2000, vol. 6, No. 5, pp. 341-359.
Neisser, Andrea et al., “Serum Antibodies Against Gangliosides andCampylobacter jejuniLipopolysaccharides in Miller Fischer Syndrome”, Infection and Immunity, 1997, vol. 65, No. 10, pp. 4038-4042.
Koga, Michiaki et al, “Close Association of IgA Anti-Ganglioside Antibodies with AntecedentCampylobacter coliInfection in Guillain-Barré and Fischer's Syndromes”, Journal of Neuroimmunology, 1998, vol. 81, pp. 138-143.
Koga, Michiaki et al., “Subclass Distribution and the Secretory Component of Serum IgA Anti-Ganglioside Antibodies in Guillain-Barré Syndrome afterCampylobacter jejuniEnteritis”, Journal of Neuroimmunology, 1999, vol. 96, pp. 245-250.
Mori, M. et al., “Haemophilus influenzaeInfection and Guillain-Barré Syndrome”, Brain, 2000, vol. 123, pp. 2171-2178.
Nevo, Yoram et al., “Acute Immune Polyneuropathies: Correlations of Serum Antibodies toCampopylobacter jejuniandHelicobacter pyloriwith Anti-GM1Antibodies and Clinical Patterns of Disease”, The Journal of Infectious Diseases, 1997, vol. 176, Suppl 2, pp. S154-S156.
McAlarney, T. et al., “Specificity and Cross-Reactivity of Anti-Galactocerebroside Antibodies”, Immunological Investigations, 1995, vol. 24, No. 4, pp. 595-606.
Ang, C.W. et al., “Guillain-Barré Syndrome- and Miller Fischer Syndrome-AssociatedCampopylobacter jejuniLipopolysaccharides Induce Anti-GM1and Anti-GQ1bAntibodies in Rabbits”, Infection and Immunity 2001, vol. 69, No. 4, pp. 2462-2469.
Petratos, Steven et al., “Antibodies Against Peripheral Myelin Glycolipids in People with HIV Infection”, Immunology and Cell Biology, 1998, vol. 76, pp. 535-541.
Gisslen, M. et al., “Cerebrospinal Fluid Antibodies Directed Against Neuron-Associated Gangliosides in HIV-1 Infection” Infection 28, 2000, No. 3, pp. 143-148.
Müller, C. et al., “Characterization of Autoantibodies to Natural Killer Cells in HIV-Infected Patients”, Scand. J. Immunol, 1996, vol. 43, pp. 583-592.
Adler, Grazyna et al., “Small Cell Lung Cancer is not Asscoiated with the Presence of Anti-Fucosyl-GM1Ganglioside Autoantibodies Reactive in Immunoenzymatic Test”, Lung Cancer, vol. 34, 2001, pp. 383-385.
Lewartowska, Aleksandra et al., “Ganglioside Reactive Antibodies of IgG and IgM Class in Sera of Patients with Differential Thyroid Cancer”, Immunology Letters, 2002, vol. 80, No. 2, pp. 129-132.
Konstandoulakis, Manousos M. et al., “Autoantibodies in the Serum of Patients with Gastric Cancer: Their Prognostic Importance”, Hybridoma, 1998, vol. 17, No. 5, pp. 431-435.
Nilsson, Olle, “Carbohydrate Antigens in Human Lung Carcinomas”, APMIS Suppl. 27, 1992, vol. 100, pp. 149-164.
Weller, Michael et al., “Ganglioside Antibodies: A Lack of Clinical Utility?”, Jorunal of Neurology, 1992, vol. 239, pp. 4
B.R.A.H.M.S. Aktiengesellschaft
Halvorson Mark
Heslin Rothenberg Farley & & Mesiti P.C.
Yu Misook
LandOfFree
Method for diagnosing neoplasms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for diagnosing neoplasms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for diagnosing neoplasms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078179